MHRA approval granted for this Ophthalmology drug: Biocon

Aflibercept, the active ingredient in YESAFILI, positions it as a biosimilar to the well-established reference product Eylea.

The Health Master

November 14, 2023

Table of Contents

Last Updated on January 3, 2024 by The Health Master

MHRA approval

MHRA approval: In a groundbreaking development, Biocon Biologics, a subsidiary of Biocon, proudly announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has granted marketing authorization for YESAFILI, a biosimilar of Aflibercept.

Follow us on WhtasApp Channel

This marks a significant milestone for Biocon Biologics and reinforces the credibility and efficacy of their innovative ophthalmology product.

MHRA’s Stamp of Approval: What It Means

The approval from the MHRA holds immense importance, as it signifies the product’s compliance with rigorous regulatory standards set by one of the leading regulatory authorities in the world.

This stamp of approval not only opens the doors for YESAFILI’s availability in the UK but also enhances its global reputation.

European Commission Gives Nod to YESAFILI’s EU Market Entry

Building on the momentum gained from MHRA’s approval, YESAFILI previously received marketing authorization approval from the European Commission (EC) for the European Union.

This green light from the EC ensures that YESAFILI can now reach a broader patient population across the EU, offering hope and advanced treatment options for various eye conditions.

YESAFILI: Revolutionizing Ophthalmology

Designed as an ophthalmology product, YESAFILI is tailored for the treatment of neovascular age-related macular degeneration (wet AMD), visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), visual impairment due to diabetic macular oedema (DME), and visual impairment due to myopic choroidal neovascularisation (myopic CNV).

YESAFILI vs. Eylea: A Comparative Analysis

Aflibercept, the active ingredient in YESAFILI, positions it as a biosimilar to the well-established reference product Eylea.

The data showcases that YESAFILI maintains comparable quality, safety, and efficacy to Eylea, providing healthcare professionals and patients with a reliable alternative.

Addressing Specific Eye Conditions

Neovascular Age-Related Macular Degeneration (wet AMD)

Wet AMD is a prevalent eye condition affecting a substantial population globally.

YESAFILI’s approval brings a ray of hope for patients dealing with this condition, offering a targeted and effective treatment option.

Macular Oedema Secondary to Retinal Vein Occlusion

The approval also extends to conditions involving macular oedema secondary to retinal vein occlusion, addressing the visual impairment associated with both branch RVO and central RVO.

Diabetic Macular Oedema (DME)

For patients grappling with visual impairment due to diabetic macular oedema, YESAFILI emerges as a promising solution, aligning with the growing need for effective treatments in diabetic care.

Myopic Choroidal Neovascularisation (Myopic CNV)

In the realm of myopic CNV, YESAFILI stands as a valuable addition to treatment options, offering a specialized approach to address visual impairment associated with this condition.

Quality, Safety, and Efficacy: Data Speaks

The journey to regulatory approval was paved with extensive studies and trials, affirming YESAFILI’s adherence to high-quality standards.

The biosimilar has demonstrated equivalent quality, safety, and efficacy compared to its reference product, Eylea, ensuring confidence among healthcare providers and patients.